Raphi Levy Sells 17,730 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 17,730 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $14.00, for a total value of $248,220.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at approximately $1,262,520. This represents a 16.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The stock was sold at an average price of $14.00, for a total value of $31,780.00.
• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total value of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total value of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Stock Performance

Alpha Tau Medical stock opened at $14.50 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. Alpha Tau Medical Ltd. has a 12 month low of $3.00 and a 12 month high of $14.75. The company has a fifty day moving average price of $11.83 and a two-hundred day moving average price of $9.33. The company has a market cap of $1.31 billion, a PE ratio of -13.94 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.36). The business had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.14 million. Research analysts expect that Alpha Tau Medical Ltd. will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DRTS. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Friday, July 17th. Barclays upped their target price on Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. HC Wainwright raised their price target on Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Piper Sandler boosted their price objective on Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research report on Tuesday, May 19th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $12.80.

Key Headlines Impacting Alpha Tau Medical

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and raised its price target to $16 from $15, suggesting additional upside from recent trading levels. The firm’s bullish stance appears to be the main catalyst supporting DRTS. HC Wainwright forecasts strong price appreciation for Alpha Tau Medical
• Positive Sentiment: Investor enthusiasm and the higher analyst target helped Alpha Tau Medical reach a new 12-month high, reinforcing positive momentum in the stock. Alpha Tau Medical sets new 12-month high
• Neutral Sentiment: HC Wainwright’s $16 target remains above the stock’s recent price, but the firm continues to forecast ongoing losses, including estimated fiscal 2026 EPS of negative $1.05 and fiscal 2027 EPS of negative $0.60. The company is developing targeted alpha-radiation therapies for solid tumors, making clinical and commercial progress important future catalysts.
• Negative Sentiment: HC Wainwright lowered its EPS estimates for every reported period from the third quarter of 2026 through fiscal 2027. The fiscal 2026 forecast was reduced notably to a loss of $1.05 per share from $0.67, while the fiscal 2027 estimate fell to a loss of $0.60 from $0.55, signaling expectations for greater near-term cash losses.
• Negative Sentiment: CFO Raphi Levy sold 17,730 shares for approximately $248,220, reducing his direct ownership by 16.43%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which makes it a less concerning signal than discretionary selling, although it may still weigh on sentiment. Raphi Levy sells Alpha Tau Medical shares
• Negative Sentiment: Alpha Tau Medical’s latest quarterly results showed a loss of $0.50 per share, substantially worse than the expected $0.14 loss, while revenue also trailed estimates. The earnings miss adds pressure to a stock that has already advanced significantly.

Institutional Trading of Alpha Tau Medical

Hedge funds have recently bought and sold shares of the company. Envestnet Asset Management Inc. acquired a new position in Alpha Tau Medical during the 3rd quarter valued at about $62,000. Bank of America Corp DE grew its position in Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after purchasing an additional 21,677 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Alpha Tau Medical in the third quarter valued at approximately $170,000. Mariner LLC increased its stake in shares of Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after purchasing an additional 80,129 shares during the period. Finally, Trifecta Capital Advisors LLC bought a new stake in shares of Alpha Tau Medical during the fourth quarter valued at approximately $48,000. 2.65% of the stock is currently owned by institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.